SPY Imaging for Surgeons

Transcription

1 SPY Imaging for Surgeons

2 Forward-Looking Statements These slides accompany an oral presentation by Novadaq Technologies, Inc., which contains forwardlooking statements. Actual results may differ materially from those expressed or implied in this presentation as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the Company s documents that are filed with the Ontario Securities Commission and can be viewed on the website 2

3 Imaging for Surgeons Improves patient outcomes of complex procedures Lowers costs to the healthcare system Diagnostic imaging Imaging 3

4 Core Technology Platform Real-time images in 2 minutes without radiation Fluorescent dye Infrared laser and image capture Software Visualization - vasculature, perfusion, lymphatics, cancer margins 4

5 First Wave Current Revenue Products adoption of core technology, growth, profitability Procedure Kits, (ICG + DRAPE) (recurring revenues) Systems for Open, Robotic and Minimally Invasive Surgeries (placement or capital) Elite Robotics CO2 Heart Laser 5

6 Second Wave Near to Market Products leverage technology platform, market leadership, diversify sales channels Wound Care 6

7 Partner LifeCell for Plastic Reconstruction, GI and Head & Neck System for Open Surgeries Launched in February 2011 Revenues from recurring consumable sales 7

8 System for Vascular and Wound Care Partner KCI for vascular surgery and wound care Signed November 30, 2011 Engineering/development phase Assessment of blood flow and perfusion in diabetic patients with vascular insufficiencies and nonhealing wounds 8

9 Robotics Functional Imaging for Robotic Surgeons Partnered with Intuitive Surgical World leader in robotic surgery - install base ~2000 (+100 per quarter) SPY Imaging integrated into system - sold as an upgradable option Capital + recurring consumable sales Launched February Partial nephrectomy - tumor margin Lymph node

10 MIS System HD visible light endoscopy similar to other scopes + SPY Imaging Enables visualization of vascular flow, perfusion and lymph nodes with visible view in the background FDA cleared - clinical/market development trials in progress 10 Projected Launch Q3 2012

11 11 Clinical and Cost Data

12 12 Breast Reconstruction - Reduced Complications

13 CMS CABG Study - Reduced Costs DRG 235 DRG 236 DRG 233 DRG 234 CMS multi-center analysis (n=376) published in August 2009 Federal Registry: overall costs reduced $ 2000 to $ 4000 per patient with SPY Savings potential >$ 650 Million /yr if SPY is used in all open heart bypass surgeries in U.S. 13

14 14 Markets and Corporate Performance

15 U.S. Market 1.8 Million Procedures LifeCell markets 819,000 procedures Robotics 131,000 procedures MIS 500,000 procedures Wound Care 402,000 procedures Annual Patients statistics represent North American market as per clinical reports and Company estimates *Other procedures include microsurgery, tumor resection, body contouring, birth defects, burns, hand surgery 15

16 Achievements Toward Broad Adoption KOL Use Stanford University of Illinois MD Anderson Johns Hopkins Duke University University of North Carolina East Cooper South Carolina NY Group for Plastic Surgery Cleveland Clinic (Florida) Henry Ford Hospital UCLA Head & Neck Glendale Memorial Emory University Bethesda Naval Hospital Montefiore Medical New York Eye & Ear Stony Brook Mayo Methodist Hospital Text Book Recommendations >40 journal publications Surgeon Reimbursement CPT: $100-$200 per injection Hospital Reimbursement ICD-9-CM billing/tracking code Clinical Additional trials underway 16

17 Early Launch Metrics Systems *includes SPY Open Plastic Systems Elite and

18 Recent Performance Open SPY Procedures* 18 *Open SPY procedures include plastic/reconstruction and cardiac surgeries

19 19 Recent Performance - Revenues

20 Recent Performance Operating Burn* *Operating Burn = cash used in operating activities changes in working capital 20

21 Platform technology and best-in-class sales channels Highlights Open Plastic, GI, Head & Neck Robotics Wound Care Core Technology Cardiac MIS SYSTEM Leveragable business model; > 1 Million procedures/year; GM 50% to 60% Low overhead costs + recurring revenues = *operating leverage* 21

22 Financial Highlights Cash $10.3 million at September 31, 2011 Convertible Debt* $4.1 million at September 31, 2011 Operating Burn Shares Outstanding approximately $0.15 million per month 32.7 million (34.9 million fully diluted**) Market Capitalization C$163.1 million as of November 22, 2011 Largest Shareholders Gagnon HIG Horizon Fairfax Note: US$ unless otherwise indicated *5.0% senior unsecured convertible debentures due 2014; face value $5.15 million, $1.88 conversion price **Net share settlement method ($4.98 stock price); treasury stock method 37.7 million (excludes conv. debt) 22

23 SPY Imaging for Surgeons